Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

RARE· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -45.3% in FY2025

Emil D. Kakkis, M.D., Ph.D. is the CEO of Ultragenyx Pharmaceutical and was paid $11.4M in FY2025 (Dec), down 17%.

Pay$100 in the stock at the end of FY20 → $17
CEO pay is from each Ultragenyx Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Emil D. Kakkis, M.D., Ph.D.FY2025
  2. 2Erik HarrisFY2025
  3. 3Eric Crombez, M.D.FY2025
  4. 4Howard HornFY2025
  5. 5Karah ParschauerFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Ultragenyx Pharmaceutical paid its 5 named executives $26.7M in total in FY2025 (Dec). CEO Emil D. Kakkis, M.D., Ph.D. was paid $11.4M of that.

Name
Emil D. Kakkis, M.D., Ph.D.President and Chief Executive Officer
Erik HarrisChief Commercial Officer and Executive Vice President
Eric Crombez, M.D.Chief Medical Officer and Executive Vice PresidentNot disclosed
Howard HornChief Financial Officer, Corporate Strategy and Executive Vice President
Karah ParschauerChief Legal Officer and Corporate Affairs, Executive Vice PresidentNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2025 (Dec) proxy of Ultragenyx Pharmaceutical names 19 peer companies for pay. Among Ultragenyx Pharmaceutical and these peers, CEO pay was 7th highest of 9 and total shareholder return was the lowest of 9.

7th highest of 9in Ultragenyx Pharmaceutical and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

9th highest of 9in Ultragenyx Pharmaceutical and its pay peers, FY2025 (Dec) by total shareholder return:

$17$523

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

Filings6

See all
Proxy statementDEF 14AMar 27, 2026FY2025
Annual report10-KFeb 18, 2026FY2025
Proxy statementDEF 14AMar 28, 2025FY2024
Annual report10-KFeb 19, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 21, 2024FY2023